Skip to main content
News > News > Dr. Shengchang Su Joins Discussion on Opportunities and Challenges of China’s Water Industry

Dr. Shengchang Su Joins Discussion on Opportunities and Challenges of China’s Water Industry

FOR IMMEDIATE RELEASE

CINCINNATI, Ohio, USA – May 21, 2015 – Open Therapeutics Director of MicrobialBots and GeRM™, Dr. Shengchang Su, joins Melinda Kruyer, CEO of Confluence, and John Mangan, Trustee of Mill Creek Watershed Council of Communities, in a round table discussion on opportunities and challenges of China’s water industry.

The discussion is hosted by the Greater Cincinnati Chinese Chamber of Commerce and moderated by John Robinson, Principal Consultant of Cornerstone China Advisor and publisher of Mandarin Environment—a newly formed media brand designed to connect Chinese investors to North American clean-tech opportunities.

The discussion takes place on May 21, 2015, from 12PM to 2PM at the Cincinnati Chinese Chamber’s downtown office located at 3 East 4th Street, Learning Center, Cincinnati OH, 45202. To register for this event, please visit the registration page [click here].

On April, 16, 2015, China announced action plan for water pollution prevention and control. The plan contains “10 measures for water” and follows the air pollution campaign that began in 2013. The 10 measures for water according to the Chinese State Council website include:

  1. Control and reduce discharge from industries, urban areas, agriculture, rural, shipping ports.
  2. Upgrading to recycle industrial water, reclaimed water, and seawater.
  3. Conservation and protection of water resources (by strict management system).
  4. Improving scientific and technical support; strengthening fundamental science.
  5. Increase market efficiency and price reform.
  6. Strict enforcement and severe punishment.
  7. Authorized discharge under strict management.
  8. Safety and strengthening protection of water bodies.
  9. More responsibility in local governments with central inspections.
  10. Improve public participation and community supervision (including public listing of performance).

 

Open Therapeutics believes synthetic biology and bioremediation plays an important role in the water action plan. Specifically, the Open Therapeutics open business model promotes and strengthens fundamental science of bioremediation in China and increase market efficiency. Additionally, bioremediation through synthetic biology based solutions can control and reduce discharge pollutions, upgrade existing infrastructure with low cost. The open model encourages safety and facilitates the mandated public participation.

View as a .PDF

Shengchang Su, PhD – Director, MicrobialBots and GeRM™ Engineering.

Dr. Shengchang Su is a bacteriologist and genetic engineer. After graduation from China Agricultural University in Beijing with a PhD in Agronomy in 2000, he received extensive training as a post-doctoral fellow in the Department of Crop Science, then worked as a research scientist in the Department of Microbiology at the University of Illinois at Urbana-Champaign between 2000 and 2007. Dr. Su moved to Cincinnati in 2007 and continued his research at the College of Medicine, the University of Cincinnati. Dr. Su is also a Visiting Scholar at the Department of Molecular Genetics, University of Cincinnati College of Medicine. Dr. Su joined Open Therapeutics as the Director, MicrobialBots and GeRM™ Engineering in 2014

About Open Therapeutics LLC

Open Therapeutics is a global biotechnology firm that rapidly prototypes synthetic biology-based products for industrial customers. We create open, patented, and proprietary bacterial (BactoBots) and viral (ViruBots) technologies. These organism-based MicrobialBots perform functions for water, chemical, and pharmaceutical industries.

Open Therapeutics is a framework supporting a global ecosystem of responsible and capable research scientists working collaboratively on development projects to reduce cost, time, and risks of developing new therapeutics applications with commercial viability. Specifically, we focus on microbial biology to understand our vast new dimension therapeutic options. But because the field of microbial biology may cause unintended consequences, a healthy dialogue must be had for how to best progress with synthetic biology.

For more information on Open Therapeutics, visit its web site at http://staging.jaded-glass.flywheelsites.com.
Contact:
Jin Kong
Phone: +1.253.592.7590
https://twitter.com/MicrobialBot or @MicrobialBot

We Believe

Open Therapeutics crowdsources orphan and dormant therapeutic intellectual properties (IP) to scientists around the world. The goal is advancing research that ordinarily has not generated a public value or been recognized. This approach particularly helps underserved scientists to collaborate with their more financially capable colleagues.

How open science helps researchers succeed:

Open access, open data, open source, and other open scholarship practices are growing in popularity and necessity. However, widespread adoption of these practices has not yet been achieved. One reason is that researchers are uncertain about how sharing their work will affect their careers.

The review of the literature demonstrates that open science is associated with increases in citations, media attention, potential collaborators, job opportunities, and funding opportunities. These findings are evidence that open science practices bring significant benefits to researchers relative to more traditional closed practices.

Secured By miniOrange